NasdaqGM - Nasdaq Real Time Price USD

Lantheus Holdings, Inc. (LNTH)

75.52

+1.34

+(1.81%)

At close: May 29 at 4:00:01 PM EDT

76.00

+0.48

+(0.64%)

After hours: May 29 at 7:14:42 PM EDT

Lantheus Holdings (NasdaqGM:LNTH) Adjusts 2025 Earnings Guidance

Lantheus Holdings (NasdaqGM:LNTH) recently adjusted its earnings guidance for 2025, reducing anticipated revenues, which has coincided with a 4% decline in its share price over the last quarter. In Q1 2025, the company reported a significant drop in net income and earnings per share, a factor that could influence investor sentiment negatively. Despite promising developments in product diagnostics, Lantheus's lowered guidance and governance changes may have added weight against broader market...

Simply Wall St. 16 days ago

LNTH
+1.81%
LNTH Q1 Earnings Call: Lantheus Lowers Outlook Amid Product Shifts and Divestitures

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.

StockStory 20 days ago

LNTH
+1.81%
Lantheus price target lowered to $120 from $134 at JonesResearch

JonesResearch lowered the firm’s price target on Lantheus (LNTH) to $120 from $134 and keeps a Buy rating on the shares following the Q1 report. With Pylarify facing competitive pressure and its net sales down 0.5% year-over- year, an ongoing business reorganization and reduced fiscal 2025 earnings guidance, the stock has faced significant negative pressure, the analyst tells investors in a research note. The firm acknowledges near-term concerns over emerging PSMA-PET competition and potential i

TipRanks 20 days ago

LNTH
+1.81%
Lantheus Holdings, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

There's been a major selloff in Lantheus Holdings, Inc. ( NASDAQ:LNTH ) shares in the week since it released its...

Simply Wall St. 20 days ago

LNTH
+1.81%
LNTH: Sale of SPECT Tilts Growth to Novel Radiopharmaceuticals

By John Vandermosten, CFA NASDAQ:LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported first quarter 2025 financial and operational results on May 7 th , producing sales of $373 million, a 1% increase over 1Q:24 levels. Pylarify, TechneLite, and Other Precision Diagnostics saw a year over year decline which was more than offset by an increase in revenue from

Zacks Small Cap Research 21 days ago

LNTH
+1.81%
Lantheus Holdings First Quarter 2025 Earnings: Misses Expectations

Lantheus Holdings ( NASDAQ:LNTH ) First Quarter 2025 Results Key Financial Results Revenue: US$372.8m (flat on 1Q...

Simply Wall St. 21 days ago

LNTH
+1.81%
Why Lantheus Holdings, Inc. (LNTH) Nosedived on Wednesday

We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Lantheus Holdings, Inc. (NASDAQ:LNTH) stands against the other stocks. The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank’s decision to […]

Insider Monkey 21 days ago

LNTH
+1.81%

^GSPC
Lantheus Holdings Inc (LNTH) Q1 2025 Earnings Call Highlights: Strategic Moves Amidst Mixed ...

Lantheus Holdings Inc (LNTH) navigates a challenging quarter with strategic acquisitions and divestitures, while adjusting its financial outlook for 2025.

GuruFocus.com 21 days ago

LNTH
+1.81%
Why Lantheus (LNTH) Shares Are Getting Obliterated Today

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell 22.2% in the afternoon session after the company reported weak first quarter 2025 results which included a significant miss on full-year EPS guidance and EPS falling short of Wall Street's estimates. Sales were flat, with a slight drop in PYLARIFY mostly offset by small gains in other parts of the business. Operating profit also fell. The real issue was the cut to full-year earnings, now seen at $6.60 to $6.70 per share,

StockStory 22 days ago

LNTH
+1.81%
Lantheus (NASDAQ:LNTH) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full-year revenue guidance of $1.57 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts’ consensus estimates.

StockStory 22 days ago

LNTH
+1.81%
Lantheus Holdings: Q1 Earnings Snapshot

On a per-share basis, the Bedford, Massachusetts-based company said it had profit of $1.02. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results missed Wall Street expectations.

Associated Press Finance 22 days ago

LNTH
+1.81%
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced plann

GlobeNewswire 22 days ago

LNTH
+1.81%
Lantheus Announces Sale of SPECT Business to SHINE Technologies

Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced a definitive agreem

GlobeNewswire 23 days ago

LNTH
+1.81%
Lantheus Earnings: What To Look For From LNTH

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be announcing earnings results tomorrow before market open. Here’s what you need to know.

StockStory 23 days ago

LNTH
+1.81%
3 Stocks Estimated To Be Up To 49.4% Below Intrinsic Value

In the current U.S. market, investors are navigating a mixed landscape with the S&P 500 and Dow Jones aiming to extend their winning streaks amid fluctuating indices and ongoing tariff discussions. As these broader economic factors play out, identifying undervalued stocks becomes crucial for those looking to capitalize on potential discrepancies between market price and intrinsic value.

Simply Wall St. 24 days ago

HQY

LNTH
+1.81%

CFG
Lantheus Holdings (NasdaqGM:LNTH) Advances Alzheimer's PET Diagnostic With Successful Trial Results

Lantheus Holdings (NasdaqGM:LNTH) announced clinical success with its MK-6240 PET radiodiagnostic, showing promise in Alzheimer’s detection, and plans an NDA submission to the FDA. Over the last quarter, Lantheus experienced a 13% price increase, likely supported by positive trial results and broader market resilience. Its earnings report reflected increased sales but lower net income, offering mixed signals. The S&P 500 and Nasdaq have been performing robustly, with strong earnings from tech...

Simply Wall St. 28 days ago

LNTH
+1.81%
Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

Company plans to file NDA in the third quarter of this yearBEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two p

GlobeNewswire 29 days ago

LNTH
+1.81%
Lantheus Holdings, Inc. (LNTH): Among Stocks with Consistent Growth to Buy Now

We recently published a list of 11 Stocks with Consistent Growth to Buy Now. In this article, we are going to take a look at where Lantheus Holdings, Inc. (NASDAQ:LNTH) stands against stocks with consistent growth to buy now. The market is clouded by friction between trading partners. But even at these uncertain times, one […]

Insider Monkey last month

LNTH
+1.81%
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights Lantheus Holdings' estimated fair value is US$205 based on 2 Stage Free Cash Flow to Equity Current share...

Simply Wall St. last month

LNTH
+1.81%
Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen min

GlobeNewswire last month

LNTH
+1.81%

Performance Overview

Return	LNTH	S&P 500 (^GSPC)
YTD	-15.58%	+0.52%
1-Year	-5.33%	+12.25%
3-Year	+7.36%	+42.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lantheus Holdings, Inc. (LNTH)

Lantheus Holdings (NasdaqGM:LNTH) Adjusts 2025 Earnings Guidance

LNTH Q1 Earnings Call: Lantheus Lowers Outlook Amid Product Shifts and Divestitures

Lantheus price target lowered to $120 from $134 at JonesResearch

Lantheus Holdings, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

LNTH: Sale of SPECT Tilts Growth to Novel Radiopharmaceuticals

Lantheus Holdings First Quarter 2025 Earnings: Misses Expectations

Why Lantheus Holdings, Inc. (LNTH) Nosedived on Wednesday

Lantheus Holdings Inc (LNTH) Q1 2025 Earnings Call Highlights: Strategic Moves Amidst Mixed ...

Why Lantheus (LNTH) Shares Are Getting Obliterated Today

Lantheus (NASDAQ:LNTH) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops

Lantheus Holdings: Q1 Earnings Snapshot

Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

Lantheus Announces Sale of SPECT Business to SHINE Technologies

Lantheus Earnings: What To Look For From LNTH

3 Stocks Estimated To Be Up To 49.4% Below Intrinsic Value

Lantheus Holdings (NasdaqGM:LNTH) Advances Alzheimer's PET Diagnostic With Successful Trial Results

Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

Lantheus Holdings, Inc. (LNTH): Among Stocks with Consistent Growth to Buy Now

Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

Performance Overview